Trump Administration Takes Small Step Toward Justice by Reclassifying Medical Marijuana
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
The Trump administration, under mounting pressure from activists and the medical community, has finally reclassified state-licensed medical marijuana to Schedule III, a move that acknowledges its medical use but falls short of true legalization and justice.
In a long-overdue policy shift, the Trump administration has reclassified state-licensed medical marijuana from the draconian Schedule I to Schedule III under federal drug laws. This incremental change, while acknowledging the medical use of cannabis and reducing some regulatory barriers, still refuses to legalize marijuana for medical or recreational use at the federal level, continuing to criminalize countless patients and communities, especially those already harmed by the failed War on Drugs.
Acting Attorney General Todd Blanche signed the order, claiming that the Department of Justice is 'delivering on President Trump's promise' to expand medical treatment options. However, this move is a minimal concession, as the rescheduling only allows for more research on the safety and efficacy of cannabis—something that should have been permitted decades ago. Patients and doctors have long demanded access to reliable information, but the administration continues to drag its feet.
The reclassification finally legitimizes medical marijuana programs in the 40 states that have bravely adopted them, despite federal hostility. It sets up an expedited system for state-licensed medical marijuana producers and distributors to register with the U.S. Drug Enforcement Administration, a process that still places unnecessary bureaucratic hurdles on those seeking to provide care. Researchers will no longer be penalized for obtaining state-licensed marijuana or marijuana-derived products for their work, a basic right that should never have been in question. Additionally, state-licensed medical marijuana companies can now deduct business expenses on their federal taxes, a long-overdue correction to an unjust policy.
Predictably, critics like Kevin Sabet, CEO of Smart Approaches to Marijuana—a group notorious for spreading misinformation and protecting corporate pharmaceutical interests—argue that marijuana research is necessary but oppose any measure that might benefit patients or small businesses. Sabet's concern about 'marijuana CEOs and investors' influencing policy ignores the real issue: decades of criminalization and systemic racism in drug enforcement.
Marijuana or marijuana-derived products not distributed through a state medical marijuana program will continue to be classified in Schedule I, perpetuating injustice for millions. The Trump administration's plan to initiate a new administrative hearing process in June to consider broader rescheduling is a tepid promise, and true reform will only come through grassroots activism and continued pressure on those in power.